Morgan Stanley raised the firm’s price target on Abbott (ABT) to $137 from $127 and keeps an Equal Weight rating on the shares. The firm continues to like the industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- ABT Earnings this Week: How Will it Perform?
- Abbott price target raised to $148 from $145 at BTIG
- Options Volatility and Implied Earnings Moves This Week, July 15 – July 18, 2025
- Abbott Laboratories Positioned for Growth: Buy Rating Supported by Strong Operational Momentum and Favorable Market Conditions
- Abbott price target raised to $157 from $155 at Citi